Park Jung-Bin, Bae Jung Ho
Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Department of Internal Medicine and Healthcare Research Institute, Healthcare System Gangnam Center, Seoul National University Hospital, Seoul, Korea.
Clin Endosc. 2025 Jan;58(1):112-120. doi: 10.5946/ce.2024.168. Epub 2024 Aug 5.
BACKGROUND/AIMS: The real-world effectiveness of computer-aided detection (CADe) systems during colonoscopies remains uncertain. We assessed the effectiveness of the novel CADe system, ENdoscopy as AI-powered Device (ENAD), in enhancing the adenoma detection rate (ADR) and other quality indicators in real-world clinical practice.
We enrolled patients who underwent elective colonoscopies between May 2022 and October 2022 at a tertiary healthcare center. Standard colonoscopy (SC) was compared to ENAD-assisted colonoscopy. Eight experienced endoscopists performed the procedures in randomly assigned CADe- and non-CADe-assisted rooms. The primary outcome was a comparison of ADR between the ENAD and SC groups.
A total of 1,758 sex- and age-matched patients were included and evenly distributed into two groups. The ENAD group had a significantly higher ADR (45.1% vs. 38.8%, p=0.010), higher sessile serrated lesion detection rate (SSLDR) (5.7% vs. 2.5%, p=0.001), higher mean number of adenomas per colonoscopy (APC) (0.78±1.17 vs. 0.61±0.99; incidence risk ratio, 1.27; 95% confidence interval, 1.13-1.42), and longer withdrawal time (9.0±3.4 vs. 8.3±3.1, p<0.001) than the SC group. However, the mean withdrawal times were not significantly different between the two groups in cases where no polyps were detected (6.9±1.7 vs. 6.7±1.7, p=0.058).
ENAD-assisted colonoscopy significantly improved the ADR, APC, and SSLDR in real-world clinical practice, particularly for smaller and nonpolypoid adenomas.
背景/目的:计算机辅助检测(CADe)系统在结肠镜检查中的实际效果仍不确定。我们评估了新型CADe系统——人工智能驱动的内镜设备(ENAD)在提高实际临床实践中的腺瘤检出率(ADR)和其他质量指标方面的有效性。
我们纳入了2022年5月至2022年10月在一家三级医疗中心接受择期结肠镜检查的患者。将标准结肠镜检查(SC)与ENAD辅助结肠镜检查进行比较。八名经验丰富的内镜医师在随机分配的CADe辅助和非CADe辅助房间进行操作。主要结果是比较ENAD组和SC组之间的ADR。
共纳入1758名性别和年龄匹配的患者,并将其平均分为两组。ENAD组的ADR显著更高(45.1%对38.8%,p = 0.010),无蒂锯齿状病变检出率(SSLDR)更高(5.7%对2.5%,p = 0.001),每次结肠镜检查的平均腺瘤数量(APC)更多(0.78±1.17对0.61±0.99;发病风险比,1.27;95%置信区间,1.13 - 1.42),且退出时间比SC组长(9.0±3.4对8.3±3.1,p < 0.001)。然而,在未检测到息肉的病例中,两组的平均退出时间无显著差异(6.9±1.7对6.7±1.7,p = 0.058)。
在实际临床实践中,ENAD辅助结肠镜检查显著提高了ADR、APC和SSLDR,特别是对于较小的和无息肉样腺瘤。